162 / Yangshengtang - LARVOL DELTA

A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: Yangshengtang Co., Ltd | N=10 ➔ 1 | Initiation date: Feb 2024 ➔ Jun 2024 | Not yet recruiting ➔ Terminated; Enrollment difficulty

Enrollment change • Trial initiation date • Trial termination • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Yangshengtang Co., Ltd

New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Yangshengtang Co., Ltd | Recruiting ➔ Completed | N=34 ➔ 20

Enrollment change • Trial completion • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=34 | Recruiting | Sponsor: Yangshengtang Co., Ltd | Trial completion date: Jul 2023 ➔ Oct 2023

Trial completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=34 | Recruiting | Sponsor: Yangshengtang Co., Ltd | Trial completion date: Aug 2022 ➔ Jul 2023 | Trial primary completion date: Aug 2022 ➔ Jul 2023

Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=34 | Recruiting | Sponsor: Yangshengtang Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=34 | Not yet recruiting | Sponsor: Yangshengtang Co., Ltd

New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation